164336-12-3

Upstream product

• 162823-37-2 3-oximino-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one-1-acetic acid 
• 7440-18-8 ruthenium 
• 14439-71-5 2'-benzoyl-2-bromo-acetanilide 
• 149620-84-8 2-(2,3-dihydro-2-oxo-5-phenylbenzo[e][1,4]diazepin-1-yl) acetic acid 
• 149620-85-9 tert-butyl 2-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4] diazepin-1-yl)acetate 
• 2835-77-0 (2-aminophenyl)(phenyl)methanone 
• 2898-08-0 2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one 

Downstream Products

• 164336-13-4 (3-tert-butoxycarbonylamino-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid 
• 164336-14-5 3-(tert-butoxycarbonyl)methylamino-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one-1-acetic acid 

Relevant academic research and scientific papers

Ras farnesyl transferase inhibitors

Benzodiazepine derivatives represented by the structure below are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases foe which inhibition of the ras farnesyl:protein transferase as indicated. STR1

RAS FARNESYL TRANSFERASE INHIBITORS

Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras famesyl:protein transferase. Pharrnaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated. Also disclosed are benzazepines of the following general formula (II) having similar utility as the aforementioned benzodiazepines